<DOC>
	<DOCNO>NCT00001422</DOCNO>
	<brief_summary>This placebo control study evaluate role fludarabine ( nucleoside analog target rest proliferate lymphocyte ) treatment moderate severe psoriotic arthritis . Patients fail least one disease modify antirheumatic drug .</brief_summary>
	<brief_title>A Controlled Trial Intermittent Fludarabine Psoriatic Arthritis</brief_title>
	<detailed_description>The efficacy toxicity immunosuppressive therapy use adenine analogue fludarabine evaluate 20 patient psoriatic arthritis , fail develop intolerable side-effects least one disease modify antirheumatic drug include sulfasalazine , gold , methoxypsoralen long wave ultraviolet A light ( PUVA ) , retinoids , methotrexate cyclosporin . In double-blind , placebo-controlled trial patient receive four month course intravenous fludarabine ( 30 mg/m ( 2 ) /day 2-3 day every 4 week total four cycle ) placebo block randomization procedure ensure group balanced disease activity . After washout period two month , patient receive placebo option cross fludarabine arm additional four month treatment . Disease activity ( skin joint ) monitor throughout study . At end study , physician patient assessment disease activity well drug-related toxicity analyze .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Ability provide inform consent aspect study full information provide . Age equal old 18 year . Psoriatic arthritis 6 month duration define follow criterion : A psoriatic skin lesion ( history psoriatic skin lesion document physician ) without nail involvement . Peripheral arthritis alone combination sacroiliitis . Patients chest expansion le 2.5 cm decrease flexion cervical lumbosacral spine flexion 50 % exclude . A negative serum test rheumatoid factor absence subcutaneous nodule . Radiographic finding ( present ) compatible psoriatic arthritis ( `` pencil cup lesion , '' osteolysis terminal phalanx , asymmetrical sacroiliitis , erosive oligoarticular arthritis spinal syndesmophytes ) . Criteria ac require diagnosis whereas criterion optional . Active arthritis 3 painful swollen joint consider capable respond drug therapy least 2 follow : Tenderness pain movement least 3 joint ( periarticular area ) . 30 minute morning stiffness ( peripheral joint spine ) . Erythrocyte sedimentation rate ( ESR ) great equal 28mm/hour Creactive protein ( CRP ) great 0.8 mg/dl . Failure respond development intolerable side effect least one follow treatment : sulfasalazine , gold retinoids , PUVA , methotrexate , azathioprine cyclosporin . A wait period equal great 4 week end previous systemic treatment require initiation fludarabine treatment . Topical treatment psoriasis ( glucocorticoid , tar , anthralin , etc . ) discontinue 2 week prior study entry . seropositive , symmetric polyarthritis . Must spondylitic form psoriatic arthritis ( spondylitis alone combination shoulder hip arthritis ) . Must arthritis mutilans . Must receive glucocorticoid dos great 10mg/day prednisone . Patients must acute chronic infection require antimicrobial therapy serious viral ( e.g. , hepatitis , herpes zoster HIV infection ) fungal infection . Patients positive PPD receive INH antituberculous therapy may exclude opinion infectious disease consultant immunosuppressive therapy contraindicate . Females must pregnant lactating . Females childbearing age must practice birth control . No preexist malignancy basal cell carcinoma . All female must negative Papanicolaou smear within 3 month period prior study entry . No history cerebrovascular accident , seizure disorder chronic neurologic disease . No history document coronary artery disease , cardiomyopathy dysrhythmia require therapy . No confound medical illness judgment investigator would pose added risk study participant ( e.g. , chronic hepatic , renal pulmonary disease ( PFTs less 70 % predict value DLCO le 60 % ) bone marrow hypoplasia ( Hb le 10 mg/dl , platelets less 100.000/dl WBC less 3.400/dl ) . No patient receive alkylating agent great equal 1 year . No patient creatinine clearance ( CrCl ) less 50 ml/min .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 1999</verification_date>
	<keyword>Adenine Analogue</keyword>
	<keyword>Apoptosis</keyword>
	<keyword>Cytokines</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Synovium</keyword>
	<keyword>Psoriatic Arthritis</keyword>
</DOC>